Viagra and Eroxon: A Molecular Insight into Erectile Dysfunction Treatments

Erectile dysfunction (ED) is a widespread health concern, affecting million of men across the globe. The development of drugs like Viagra and Eroxon has revolutionized its treatment. This blog post explore the molecular mechanisms of how these drugs work, offering a deeper understanding of their effectiveness in treating ED.

Understanding Erectile Dysfunction

ED is defined by a man's inability to attain or sustain an erection adequate for satisfactory sexual activity. ED may arise from a variety of causes, including psychological, neurological, hormonal, arterial, or cavernosal issues, or a combination of these factors. The molecular basis of an erection is predominantly the regulation of blood flow to the penile tissue (1).

Viagra: The Breakthrough in ED Treatment

Viagra, known generically as Sildenafil, was the first highly effective oral treatment for ED. Approved by the FDA in 1998, it marked a significant breakthrough in ED treatment.

Molecular Mechanism of Viagra

Viagra works by inhibiting an enzyme called PDE5 (phosphodiesterase type 5). During sexual stimulation, NO (nitric oxide) is released from endothelial cells in the corpus cavernosum, part of the penis (Figure 1 below). NO diffuses into smooth muscle cells and activates an enzyme (guanylate cyclase), which converts a molecule called GTP (Guanosine-5'-triphosphate) into cGMP (cyclic guanosine monophosphate). cGMP causes smooth muscle relaxation in the corpus cavernosum, allowing for increased blood flow and an erection. PDE5 converts cGMP into an inactive form called GMP (guanosine monophosphate), thus inhibiting erectile function. Viagra's inhibition of PDE5 results in increased accumulation of cGMP, leading to enhanced smooth muscle relaxation and erection in response to sexual stimulation (2).

Figure 1. Mechanism of Viagra and Eroxon. See text for description.

Eroxon: An Emerging Alternative

Eroxon, approved by the FDA in 2023, is a topical gel formulation being developed as a potential new treatment for ED. Unlike Viagra, which is taken orally, Eroxon is applied directly to the penis.

Molecular Mechanism of Eroxon

Eroxon's primary mechanism of action is through the delivery of glyceryl trinitrate (nitroglycerin), a compound that releases NO (Figure 1). NO is a potent vasodilator as explained above; when applied topically, it penetrates the skin, increasing blood flow to the penile tissue. This mechanism directly enhances the natural erectile response to sexual stimulation by increasing NO availability in the corpus cavernosum, similar to the body's physiological process (3).

Comparing Viagra and Eroxon

While both Viagra and Eroxon work by enhancing the effects of NO, their modes of administration and onset of action differ. Viagra, as an oral medication, generally takes about 30 to 60 minutes to become effective, whereas Eroxon, being a topical agent, is expected to work within 5 to 10 minutes, offering a potentially quicker onset of action (3).

Summary

The development of Viagra and Eroxon represents significant advancements in the treatment of erectile dysfunction. By understanding their molecular mechanisms, we gain insight into how these treatments work at a cellular level, providing effective solutions for ED. As research continues, these insights pave the way for new and improved therapies for sexual dysfunction.

References and further reading

1. Erectile dysfunction. New England Journal of Medicine.

2. Oral sildenafil in the treatment of erectile dysfunction. New England Journal of Medicine.

3. Efficacy and safety of MED2005, a topical glyceryl trinitrate formulation, in the treatment of erectile dysfunction: a randomized crossover study. The Journal of Sexual Medicine.